Isomorphic Labs has a number of its drug programs in the pre-clinical stage.
Mostly true True in substance, wrong in a detail.
Factual: Statements about the present or the past, checked against the record: did they hold up?
The second judge would not resolve this claim; the verdict shown is the first judge's.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
Judge as of 2026-05-27. True: Isomorphic Labs' official announcements, filings or partner disclosures, or credible reporting, show that on that date it had more than one drug program (its own or partnered) at the pre-clinical stage, meaning past discovery or hit-finding, in IND-enabling or similar pre-clinical development, and not yet in human trials. Mostly true: it had pre-clinical programs, but only one or two, so 'a bunch' is a slight overstatement, or one detail of the stage labelling is loosely used. Mixed: the evidence is ambiguous about whether its programs were pre-clinical or still in early discovery. Mostly false: its programs were mainly at the discovery stage, with at most an early move toward pre-clinical work. False: the evidence shows Isomorphic had no programs at the pre-clinical stage on that date (for example, all were still in discovery, or all had been dropped).
Set before the research began.
Evidence (10)
-
E1 AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever BioSpace · 13 May 2026
“Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets.”
-
E2 How Demis Hassabis is leading Google through an innovator’s dilemma—and made OpenAI declare 'code red' | Fortune Fortune · 11 February 2026 Own record
“And we are already in pre-clinical trials, very early stage, for some cancer drugs.”
-
E3 How Demis Hassabis is leading Google through an innovator’s dilemma—and made OpenAI declare 'code red' | Fortune Fortune · 11 February 2026 Own record
“We have like 17 drug programs active already, and we plan to eventually go to hundreds.”
-
E4 Demis Hassabis's Isomorphic Labs: $2.7B Raised, 2026 StartupHub.ai · 8 June 2026
“At the World Economic Forum in Davos in January 2026, Hassabis confirmed that an AI-designed cancer drug candidate is scheduled to enter Phase 1 clinical trials before the end of 2026, a revision from an earlier target of end-2025.”
-
E5 How Demis Hassabis is leading Google through an innovator’s dilemma—and made OpenAI declare 'code red' | Fortune Fortune · 11 February 2026 Own record
“And we are already in pre-clinical trials, very early stage, for some cancer drugs.”
-
E6 How Demis Hassabis is leading Google through an innovator’s dilemma—and made OpenAI declare 'code red' | Fortune Fortune · 11 February 2026 Own record
“We have like 17 drug programs active already, and we plan to eventually go to hundreds.”
-
E7 Does Isomorphic Labs have what it takes to revolutionize drugmaking? - The Boston Globe The Boston Globe (republished from STAT) · 21 October 2026
“In interviews with STAT, executives confirmed the company is still in preclinical development, but declined to say if they still anticipate meeting the human trial goalpost.”
-
E8 Does Isomorphic Labs have what it takes to revolutionize drugmaking? - The Boston Globe The Boston Globe (republished from STAT) · 21 October 2026
“Wolf suggested that Isomorphic has some drug candidates in the late stages of preclinical development.”
-
E9 Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine Isomorphic Labs · 12 May 2026 Own record
“The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic.”
-
E10 The $2.7B Question: How Do We Know If Isomorphic's AI Works? BiopharmaTrend · 30 September 2026
“Almost nothing is disclosed. There is no named candidate, no named target and no program count.”
Reasoning
STAT's October 2026 reporting (E7) says executives confirmed Isomorphic is "still in preclinical development". The word "still" suggests the company had been at that stage for some time before October 2026, though the article does not say since when. The same reporting says Wolf suggested Isomorphic has "some drug candidates" in late preclinical development (E8), and E1 and E4 indicate the company had not yet reached human trials. However, no source independent of the company gives a program count (E10), so it is not shown whether "a bunch" overstates the number, and the verdict is mostly true rather than true.
Cite this claim
Demis Hassabis, “Isomorphic Labs has a number of its drug programs in the pre-clinical stage.” (said 27 May 2026). Verdict: mostly true. Reliability API, claim c_f3c695285e1f, method 0.1.0+c876030c, dataset release v1.1.2. https://epistacklabs.com/claims/c_f3c695285e1f
This claim is in dataset release v1.1.2, with the same verdict.
Reply to this claim
More factual claims by Demis Hassabis
-
Resolved true
“Hard to believe it’s been 10 years since AlphaGo!”
-
Resolved true
“It was a huge honour to meet with President @Jaemyung_Lee in Seoul.”
Demis Hassabis met South Korean President Lee Jae-myung in Seoul.
-
Mixed
“I got into AI in the first place because I was interested in all the big questions in the world, the nature of reality, nature of consciousness, these kinds of things.”
-
Mostly true
“I think that’s why I decided from a very young age to do AI”
-
Resolved true
“I think maybe Black & White was the game that I worked on early stages of that, that had still probably the best AI, learning AI, in it.”
Verdicts are made automatically; how verdicts are made.